TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 28 filers reported holding TRACON PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24 | -42.9% | 134,538 | -6.2% | 0.00% | – |
Q2 2023 | $42 | -86.8% | 143,484 | -14.9% | 0.00% | – |
Q1 2023 | $319 | +58.7% | 168,600 | +24.8% | 0.00% | – |
Q4 2022 | $201 | -99.8% | 135,049 | +98.9% | 0.00% | – |
Q3 2022 | $113,000 | +7.6% | 67,900 | +29.1% | 0.00% | – |
Q2 2022 | $105,000 | +36.4% | 52,600 | +80.1% | 0.00% | – |
Q1 2022 | $77,000 | -86.8% | 29,200 | -86.2% | 0.00% | -100.0% |
Q4 2021 | $584,000 | -50.8% | 211,000 | -31.3% | 0.00% | -50.0% |
Q3 2021 | $1,188,000 | +5.5% | 306,976 | +76.9% | 0.00% | +100.0% |
Q2 2021 | $1,126,000 | -43.1% | 173,535 | -27.9% | 0.00% | -50.0% |
Q1 2021 | $1,980,000 | +0.1% | 240,600 | +42.3% | 0.00% | 0.0% |
Q4 2020 | $1,978,000 | +369.8% | 169,100 | +107.5% | 0.00% | – |
Q3 2020 | $421,000 | -22.6% | 81,500 | -70.6% | 0.00% | – |
Q2 2020 | $544,000 | +38.1% | 277,396 | +19.7% | 0.00% | – |
Q1 2020 | $394,000 | +11.0% | 231,729 | +52.9% | 0.00% | – |
Q4 2019 | $355,000 | – | 151,529 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 4,764,508 | $848,082 | 0.28% |
Ikarian Capital, LLC | 2,765,530 | $492,265 | 0.06% |
JOHNSON & JOHNSON | 84,003 | $14,953 | 0.01% |
BOOTHBAY FUND MANAGEMENT, LLC | 258,844 | $46,074 | 0.00% |
BlackRock Inc. | 267,821 | $47,673 | 0.00% |
Bank of New York Mellon Corp | 10,259 | $1,826 | 0.00% |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 15,835 | $2,819 | 0.00% |
Truvestments Capital LLC | 318 | $57 | 0.00% |
Tower Research Capital LLC (TRC) | 10,407 | $1,852 | 0.00% |
Cutler Group LLC / CA | 1,200 | $0 | 0.00% |